Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and... see more

Recent & Breaking News (NDAQ:AZN)

CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

Business Wire 2 days ago

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Business Wire 3 days ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

Business Wire 5 days ago

Q1 2024 results

Business Wire 9 days ago

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

Business Wire April 16, 2024

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Business Wire April 11, 2024

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Business Wire April 5, 2024

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

Business Wire April 5, 2024

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Business Wire April 5, 2024

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Business Wire April 2, 2024

VOYDEYA(TM) approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Business Wire April 1, 2024

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

Business Wire March 25, 2024

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

Business Wire March 19, 2024

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Business Wire March 18, 2024

AstraZeneca announces initiation of THARROS - a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD

Business Wire March 13, 2024

Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

Canada NewsWire February 26, 2024

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Business Wire February 23, 2024

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Business Wire February 19, 2024

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Business Wire February 19, 2024

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Business Wire February 19, 2024